001     136672
005     20240229105053.0
024 7 _ |a 10.1007/s00401-018-1888-x
|2 doi
024 7 _ |a pmid:30019219
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:45149186
|2 altmetric
037 _ _ |a DKFZ-2018-01140
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Cavalli, Florence M G
|b 0
245 _ _ |a Heterogeneity within the PF-EPN-B ependymoma subgroup.
260 _ _ |a Berlin
|c 2018
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680521273_22927
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Posterior fossa ependymoma comprise three distinct molecular variants, termed PF-EPN-A (PFA), PF-EPN-B (PFB), and PF-EPN-SE (subependymoma). Clinically, they are very disparate and PFB tumors are currently being considered for a trial of radiation avoidance. However, to move forward, unraveling the heterogeneity within PFB would be highly desirable. To discern the molecular heterogeneity within PFB, we performed an integrated analysis consisting of DNA methylation profiling, copy-number profiling, gene expression profiling, and clinical correlation across a cohort of 212 primary posterior fossa PFB tumors. Unsupervised spectral clustering and t-SNE analysis of genome-wide methylation data revealed five distinct subtypes of PFB tumors, termed PFB1-5, with distinct demographics, copy-number alterations, and gene expression profiles. All PFB subtypes were distinct from PFA and posterior fossa subependymomas. Of the five subtypes, PFB4 and PFB5 are more discrete, consisting of younger and older patients, respectively, with a strong female-gender enrichment in PFB5 (age: p = 0.011, gender: p = 0.04). Broad copy-number aberrations were common; however, many events such as chromosome 2 loss, 5 gain, and 17 loss were enriched in specific subtypes and 1q gain was enriched in PFB1. Late relapses were common across all five subtypes, but deaths were uncommon and present in only two subtypes (PFB1 and PFB3). Unlike the case in PFA ependymoma, 1q gain was not a robust marker of poor progression-free survival; however, chromosome 13q loss may represent a novel marker for risk stratification across the spectrum of PFB subtypes. Similar to PFA ependymoma, there exists a significant intertumoral heterogeneity within PFB, with distinct molecular subtypes identified. Even when accounting for this heterogeneity, extent of resection remains the strongest predictor of poor outcome. However, this biological heterogeneity must be accounted for in future preclinical modeling and personalized therapies.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Hübner, Jens-Martin
|0 P:(DE-He78)a8c698e0904394407c5261932915daa5
|b 1
|e First author
700 1 _ |a Sharma, Tanvi
|0 P:(DE-He78)36e1ec4777d5b7887344177dca41eae9
|b 2
|e First author
700 1 _ |a Luu, Betty
|b 3
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 4
700 1 _ |a Zapotocky, Michal
|b 5
700 1 _ |a Mack, Stephen C
|b 6
700 1 _ |a Witt, Hendrik
|0 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
|b 7
700 1 _ |a Lin, Tong
|b 8
700 1 _ |a Shih, David J H
|b 9
700 1 _ |a Ho, Ben
|b 10
700 1 _ |a Santi, Mariarita
|b 11
700 1 _ |a Emery, Lyndsey
|b 12
700 1 _ |a Hukin, Juliette
|b 13
700 1 _ |a Dunham, Christopher
|b 14
700 1 _ |a McLendon, Roger E
|b 15
700 1 _ |a Lipp, Eric S
|b 16
700 1 _ |a Gururangan, Sridharan
|b 17
700 1 _ |a Grossbach, Andrew
|b 18
700 1 _ |a French, Pim
|b 19
700 1 _ |a Kros, Johan M
|b 20
700 1 _ |a van Veelen, Marie-Lise C
|b 21
700 1 _ |a Rao, Amulya A Nageswara
|b 22
700 1 _ |a Giannini, Caterina
|b 23
700 1 _ |a Leary, Sarah
|b 24
700 1 _ |a Jung, Shin
|b 25
700 1 _ |a Faria, Claudia C
|b 26
700 1 _ |a Mora, Jaume
|b 27
700 1 _ |a Schüller, Ulrich
|b 28
700 1 _ |a Alonso, Marta M
|b 29
700 1 _ |a Chan, Jennifer A
|b 30
700 1 _ |a Klekner, Almos
|b 31
700 1 _ |a Chambless, Lola B
|b 32
700 1 _ |a Hwang, Eugene I
|b 33
700 1 _ |a Massimino, Maura
|b 34
700 1 _ |a Eberhart, Charles G
|b 35
700 1 _ |a Karajannis, Matthias A
|b 36
700 1 _ |a Lu, Benjamin
|b 37
700 1 _ |a Liau, Linda M
|b 38
700 1 _ |a Zollo, Massimo
|b 39
700 1 _ |a Ferrucci, Veronica
|b 40
700 1 _ |a Carlotti, Carlos
|b 41
700 1 _ |a Tirapelli, Daniela P C
|b 42
700 1 _ |a Tabori, Uri
|b 43
700 1 _ |a Bouffet, Eric
|b 44
700 1 _ |a Ryzhova, Marina
|b 45
700 1 _ |a Ellison, David W
|b 46
700 1 _ |a Merchant, Thomas E
|b 47
700 1 _ |a Gilbert, Mark R
|b 48
700 1 _ |a Armstrong, Terri S
|b 49
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 50
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 51
700 1 _ |a Taylor, Michael D
|b 52
700 1 _ |a Aldape, Kenneth
|b 53
700 1 _ |a Pajtler, Kristian
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 54
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 55
|e Last author
700 1 _ |a Ramaswamy, Vijay
|0 0000-0002-6557-895X
|b 56
773 _ _ |a 10.1007/s00401-018-1888-x
|g Vol. 136, no. 2, p. 227 - 237
|0 PERI:(DE-600)1458410-4
|n 2
|p 227 - 237
|t Acta neuropathologica
|v 136
|y 2018
|x 1432-0533
909 C O |p VDB
|o oai:inrepo02.dkfz.de:136672
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)a8c698e0904394407c5261932915daa5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)36e1ec4777d5b7887344177dca41eae9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)046fd145f1008f83f6236580727bbc0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 50
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 51
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 54
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 55
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21